The CHMP positive opinion was based on the findings from the GO-AHEAD study, which demonstrated significant clinical improvement in patients with active nr-axial SpA treated with golimumab, compared ...

Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.

Merck & Co. Inc. MRK and Johnson & Johnson JNJ announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion in favor of expanding ...

Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

HORSHAM, Pa. and KENILWORTH, N.J., April 13 - Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that Health Canada has grant -- In combination with methotrexate ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

LEIDEN, The Netherlands, Sept. 23, 2013 /PRNewswire/ -- Janssen Biologics B.V. ("Janssen") announced today that the European Commission has approved SIMPONI® (golimumab) for the treatment of ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...